Antiepileptic drug therapy: does mechanism of action matter?

Antiepileptic drug discovery: does mechanism of action matter? Epilepsy Behav (2011) 1.40

Glyoxalase 1 and its substrate methylglyoxal are novel regulators of seizure susceptibility. Epilepsia (2013) 0.87

Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci (2013) 0.80

Seeking the Rational (or at least avoiding the irrational). Epilepsy Curr (2015) 0.80

Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. Eur J Clin Pharmacol (2014) 0.79

Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models. OA Alcohol (2013) 0.79

Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.78

The adolescent or adult with generalized tonic-clonic seizures. Ann Indian Acad Neurol (2012) 0.78

Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective. Front Pharmacol (2015) 0.77

The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord (2015) 0.77

Allosteric modulation of sigma-1 receptors elicits anti-seizure activities. Br J Pharmacol (2015) 0.76

Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy. Acta Neurol Scand (2016) 0.75

Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy. Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75

Sodium Channel Blockers in the Treatment of Epilepsy. CNS Drugs (2017) 0.75

A probabilistic method for determining cortical dynamics during seizures. J Comput Neurosci (2015) 0.75

ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03

15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21

Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain (2009) 3.96

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93

Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69

Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol (2013) 3.06

Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab (2009) 2.78

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74

Retracted Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet (2003) 2.70

Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia (2012) 2.45

Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov (2010) 2.22

A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet (2009) 2.12

Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain (2013) 1.95

The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol (2005) 1.95

Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol (2009) 1.94

Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia (2002) 1.91

Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia (2002) 1.82

International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82

Sudden unexpected death in epilepsy: a search for risk factors. Epilepsy Behav (2006) 1.79

Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci (2004) 1.79

Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76

Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73

Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69

Predictors of pharmacoresistant epilepsy. Epilepsy Res (2007) 1.65

GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest (2008) 1.60

Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet (2013) 1.59

Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56

Panayiotopoulos syndrome: a consensus view. Dev Med Child Neurol (2006) 1.56

A mutation in the GABA(A) receptor alpha(1)-subunit is associated with absence epilepsy. Ann Neurol (2006) 1.55

Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia (2012) 1.52

Genetic testing in the epilepsies--report of the ILAE Genetics Commission. Epilepsia (2010) 1.51

Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet (2012) 1.48

Nervous system KV7 disorders: breakdown of a subthreshold brake. J Physiol (2008) 1.47

Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45

Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain (2008) 1.41

The localizing yield of sphenoidal and anterior temporal electrodes in ictal recordings: a comparison study. Epilepsia (2002) 1.41

Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol (2014) 1.40

Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40

De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet (2013) 1.40

Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38

A graded system to categorize drug-resistant epilepsy. Epilepsia (2010) 1.37

Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35

Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. J Physiol (2008) 1.35

Seizures following picornavirus infection. Epilepsia (2008) 1.31

The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30

Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27

CLCN2 variants in idiopathic generalized epilepsy. Nat Genet (2009) 1.26

Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia (2009) 1.26

Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy Res (2010) 1.25

A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons. J Neurosci (2006) 1.24

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24

Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. Mol Pharmacol (2007) 1.24

Discovery of antiepileptic drugs. Neurotherapeutics (2007) 1.24

Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23

Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II. Brain (2002) 1.23

An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23

Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia (2013) 1.22

Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol (2011) 1.22

Axon initial segment dysfunction in a mouse model of genetic epilepsy with febrile seizures plus. J Clin Invest (2010) 1.21

DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol (2014) 1.21

Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res (2007) 1.20

Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20

Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia (2011) 1.20

KV7 channelopathies. Pflugers Arch (2010) 1.20

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20

Skeletal muscle channelopathies. J Neurol (2002) 1.20

Genetic mechanisms in idiopathic epilepsies. Dev Med Child Neurol (2008) 1.19

Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19

Epileptic nystagmus: two case reports, clinical and pathophysiological review of the literature. J Neurol (2006) 1.18

Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum Mol Genet (2003) 1.17

Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17

Two novel CLCN2 mutations accelerating chloride channel deactivation are associated with idiopathic generalized epilepsy. Hum Mutat (2009) 1.16

Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16

Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy. Brain (2010) 1.16

Evaluation of the positional candidate gene CHRNA7 at the juvenile myoclonic epilepsy locus (EJM2) on chromosome 15q13-14. Epilepsy Res (2002) 1.14

Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J Neuropathol Exp Neurol (2010) 1.14

GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord (2009) 1.14

Differential roles of S6 domain hinges in the gating of KCNQ potassium channels. Biophys J (2005) 1.13

Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther (2009) 1.10

Eryptosis, a window to systemic disease. Cell Physiol Biochem (2008) 1.10

Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10

EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 1.07

Exploration of the genetic architecture of idiopathic generalized epilepsies. Epilepsia (2006) 1.07

Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07

Rare exonic deletions of the RBFOX1 gene increase risk of idiopathic generalized epilepsy. Epilepsia (2013) 1.07

Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07

Epilepsy after head injury. Curr Opin Neurol (2004) 1.06

C-terminal interaction of KCNQ2 and KCNQ3 K+ channels. J Physiol (2003) 1.05

Theiler's virus infection chronically alters seizure susceptibility. Epilepsia (2009) 1.05

Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res (2004) 1.05

Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04